 |
8 Diseases |  |
0 Trials |
|
0 Trials |  |
22 News |  |
- || universal flu vaccine (M-001) / BiondVax
Clinical, Journal: Safety and immunogenicity of Multimeric-001 (M-001) followed by seasonal quadrivalent inactivated influenza vaccine in young adults - A randomized clinical trial. (Pubmed Central) - Apr 11, 2023
P2
M-001 administration induced a subset of polyfunctional CD4+
- ||||||| M-001 / BiondVax
Trial completion: A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine (clinicaltrials.gov) - Mar 10, 2021
P3, N=12463, Completed, Sponsor: BiondVax Pharmaceuticals ltd.
M-001 administration induced a subset of polyfunctional CD4+ Active, not recruiting --> Completed
- ||||| M-001 / BiondVax
Enrollment closed: A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine (clinicaltrials.gov) - Feb 17, 2020
P3, N=12463, Active, not recruiting, Sponsor: BiondVax Pharmaceuticals ltd.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||| M-001 / BiondVax
Enrollment open: A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine (clinicaltrials.gov) - Apr 4, 2019
P3, N=9630, Recruiting, Sponsor: BiondVax Pharmaceuticals ltd.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | universal flu vaccine (M-001) / Scinai Immunotherap
Trial completion: Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine (clinicaltrials.gov) - Mar 1, 2019
P2, N=120, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | universal flu vaccine (M-001) / Scinai Immunotherap
Enrollment closed: Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine (clinicaltrials.gov) - Jul 23, 2018
P2, N=120, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | universal flu vaccine (M-001) / Scinai Immunotherap
Enrollment open: Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine (clinicaltrials.gov) - Mar 30, 2018
P2, N=120, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||||||| M-001 / BiondVax
New P3 trial: A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine (clinicaltrials.gov) - Mar 1, 2018
P3, N=9630, Not yet recruiting, Sponsor: BiondVax Pharmaceuticals ltd.
- |||| M-001 / BiondVax
Trial completion, Phase classification: Assess the Safety and Immunogenicity of M-001 as A Standalone Influenza Vaccine and as A H5N1 Vaccine Primer in Adults (clinicaltrials.gov) - Feb 9, 2018
P2b, N=224, Completed, Sponsor: BiondVax Pharmaceuticals ltd.
Not yet recruiting --> Recruiting Recruiting --> Completed | Phase classification: P2 --> P2b
- | universal flu vaccine (M-001) / Scinai Immunotherap
Enrollment change, Trial initiation date, Trial primary completion date: Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine (clinicaltrials.gov) - Nov 27, 2017
P2, N=120, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | Phase classification: P2 --> P2b N=240 --> 120 | Initiation date: Dec 2017 --> Mar 2018 | Trial primary completion date: Jun 2018 --> Jan 2019
- | universal flu vaccine (M-001) / Scinai Immunotherap
New P2 trial: Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine (clinicaltrials.gov) - Feb 23, 2017
P2, N=240, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- ||||| M-001 / BiondVax
New P2 trial: Assess the Safety and Immunogenicity of M-001 as A Standalone Influenza Vaccine and as A H5N1 Vaccine Primer in Adults (clinicaltrials.gov) - Feb 25, 2016
P2, N=222, Recruiting, Sponsor: BiondVax Pharmaceuticals ltd.
- | M-001 / BiondVax
Trial completion: Phase II Study to Assess Safety & Immunogenicity of Multimeric-001 Influenza Vaccine, Followed by TIV (clinicaltrials.gov) - Feb 23, 2016
P2, N=37, Completed, Sponsor: BiondVax Pharmaceuticals ltd.
N=240 --> 120 | Initiation date: Dec 2017 --> Mar 2018 | Trial primary completion date: Jun 2018 --> Jan 2019 Recruiting --> Completed
- | M-001 / BiondVax
New P2 trial: Phase II Study to Assess Safety & Immunogenicity of Multimeric-001 Influenza Vaccine, Followed by TIV (clinicaltrials.gov) - Nov 18, 2014
P2, N=36, Recruiting, Sponsor: BiondVax Pharmaceuticals ltd.
- || universal flu vaccine (M-001) / Scinai Immunotherap
Trial primary completion date: A Study to Assess the Safety and Immunogenicity of M-001 Influenza Vaccine as a Primer to TIV in Elderly Volunteers (clinicaltrials.gov) - May 11, 2014
P2, N=120, Completed, Sponsor: BiondVax Pharmaceuticals ltd.
Recruiting --> Completed Trial primary completion date: Nov 2011 --> Jan 2012
- || universal flu vaccine (M-001) / Scinai Immunotherap
Trial completion date: A Study to Assess the Safety and Immunogenicity of M-001 Influenza Vaccine as a Primer to TIV in Elderly Volunteers (clinicaltrials.gov) - May 11, 2014
P2, N=120, Completed, Sponsor: BiondVax Pharmaceuticals ltd.
Trial primary completion date: Nov 2011 --> Jan 2012 Trial completion date: Dec 2011 --> Jan 2012
- |||| universal flu vaccine (M-001) / Scinai Immunotherap
Trial completion: A Study to Assess the Safety and Immunogenicity of M-001 Influenza Vaccine as a Primer to TIV in Elderly Volunteers (clinicaltrials.gov) - May 11, 2014
P2, N=120, Completed, Sponsor: BiondVax Pharmaceuticals ltd.
Trial completion date: Dec 2011 --> Jan 2012 Recruiting --> Completed
- |||| universal flu vaccine (M-001) / BiondVax
Trial completion: A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers (clinicaltrials.gov) - Jul 29, 2012
P1/2, N=60, Completed, Sponsor: BiondVax Pharmaceuticals ltd.
Recruiting --> Completed Recruiting --> Completed
- ||| universal flu vaccine (M-001) / Scinai Immunotherap
Enrollment change: Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001) (clinicaltrials.gov) - Jul 29, 2012
P2, N=200, Completed, Sponsor: BiondVax Pharmaceuticals ltd.
Recruiting --> Completed N=160 --> 200
- |||| universal flu vaccine (M-001) / Scinai Immunotherap
Trial completion: Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001) (clinicaltrials.gov) - Jul 29, 2012
P2, N=200, Completed, Sponsor: BiondVax Pharmaceuticals ltd.
N=160 --> 200 Not yet recruiting --> Completed
- ||||| universal flu vaccine (M-001) / Scinai Immunotherap
New P2 trial: A Study to Assess the Safety and Immunogenicity of M-001 Influenza Vaccine as a Primer to TIV in Elderly Volunteers (clinicaltrials.gov) - Aug 16, 2011
P2, N=120, Recruiting, Sponsor: BiondVax Pharmaceuticals ltd.